Overview

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The study was an open label, balanced, randomized, two-treatment, four-period, two sequence, single oral dose, crossover, fully replicate bioequivalence study of two formulations of Valsartan 320 mg under fasting conditions.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Valsartan